TVGN
Tevogen Bio Holdings Inc.NASDAQHealthcare$4.46-0.45%ClosedMarket Cap: $18.1M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-2.01
P/S
0.00
EV/EBITDA
-0.89
DCF Value
$-1.68
FCF Yield
-61.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
316.0%
ROA
-599.5%
ROIC
3698.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-4.7M | $-1.79 |
| FY 2025 | $0.00 | $-26.3M | $-8.08 |
| Q3 2025 | $0.00 | $-5.7M | $-1.50 |
| Q2 2025 | $0.00 | $-5.5M | $-1.53 |
Analyst Ratings
View AllD. Boral CapitalHold
2026-03-04D. Boral CapitalBuy
2026-03-03D. Boral CapitalBuy
2025-11-20D. Boral CapitalBuy
2025-09-04D. Boral CapitalBuy
2025-08-04Trading Activity
Insider Trades
View AllFlomenberg Nealofficer: See Remarks
SellTue Mar 17
Flomenberg Nealofficer: See Remarks
SellTue Mar 17
Flomenberg Nealofficer: See Remarks
SellTue Mar 17
Saadi Ryan H.director, 10 percent owner, officer: Chief Executive Officer
SellMon Dec 22
Desai Kirtiofficer: Chief Financial Officer
SellMon Dec 15
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.30
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.